Who was studied, and how
One number in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 4 other studies
7,769people with cardiovascular disease, in this paper
The trial randomly assignedassigned by chance
pitavastatin 4 mg daily
placebo
No clear effect on major non-CVD events−8%
randomisedthe abstract, start to end
… (hazard ratio [HR], cause-specific: 0.92, 95% CI 0.76-1.13; p=0.44).
← favours treatmentfavours comparator →
could be chanceMajor non-CVD events (including AIDS-defining events, non-AIDS-defining cancers, renal disease, and liver disease)pitavastatin 4 mg daily vs placebo
HR 0.920.76–1.13
StatinsAdverse events & safety
Statins × adverse events & safetyharms?mixed
unlikelylikely
0.160.20 without it
← favours treatmentfavours comparator →
1 / 6